Acacia Bay Leaf Beef Liver Black Pepper Corticotro

證據等級: L5

預測適應症: 0 個

Multi-Component Allergen Mixture: Repurposing Evaluation Unavailable

One-Sentence Summary

This candidate is a complex multi-ingredient mixture containing 20 components — including corticotropin, histamine dihydrochloride, and various botanical/biological allergens — that is not currently marketed and has no registered indication on record. The TxGNN model did not generate any repurposing predictions for this candidate, likely because the multi-component nature of the product could not be resolved to a single DrugBank entry. As a result, no repurposing direction can be evaluated at this time.

Quick Overview

Item	Content
Original Indication	Not on record
Predicted New Indication	None generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — No prediction, no studies
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This product is listed under a single INN string comprising 20 distinct components:

ACACIA · BAY LEAF · BEEF LIVER · BLACK PEPPER · CORTICOTROPIN · DIANTHUS SUPERBUS FLOWERING TOP · EUCALYPTUS GUM · FIG · GREEN OLIVE · HISTAMINE DIHYDROCHLORIDE · LIGUSTRUM LUCIDUM SEED · LIRIODENDRON TULIPIFERA WHOLE · MAGNOLIA X ALBA WHOLE · NERIUM OLEANDER WHOLE · POPULUS TREMULOIDES POLLEN · PROSOPIS CINERARIA WOOD · SALIX LUTEA POLLEN · SAMBUCUS NIGRA FLOWER · SUS SCROFA ADRENAL GLAND · SYMPHORICARPOS ALBUS FRUIT

The ingredient profile — combining multiple aeroallergens (tree and grass pollens, plant extracts) with histamine dihydrochloride (a standard positive control for skin-prick testing) and corticotropin (ACTH) — strongly suggests this is an allergy diagnostic panel or allergen immunotherapy preparation, rather than a conventional small-molecule drug.

TxGNN operates at the level of individual DrugBank-mapped compounds. Because no DrugBank ID could be assigned to this composite product, the model returned no predictions. This is an expected system limitation for complex biologics and allergen mixtures — not an indication that the product lacks clinical value.

Clinical Trial Evidence

Currently no related clinical trials registered.

(No disease target was identified for querying.)

Literature Evidence

Currently no related literature available.

(No disease target was identified for querying.)

US Market Information

This product has no US market authorization on record. No NDA table can be generated.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug interaction data were not retrievable for this multi-component product. Individual components — particularly corticotropin and histamine dihydrochloride — carry their own established safety profiles and should be reviewed separately.)

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline cannot process this candidate as-is because the multi-component mixture could not be resolved to a DrugBank node, making graph-based repurposing prediction impossible. There is no original indication on record and no predicted new indication to evaluate.

To proceed, the following is needed:

Decompose the mixture: Determine which single active ingredient (if any) is the primary therapeutic agent and submit it as a standalone candidate — for example, corticotropin (DB01285) or histamine dihydrochloride (DB01655).
Clarify product intent: Confirm whether this is an allergy diagnostic reagent, an immunotherapy formulation, or a compounded product, as each pathway requires a different regulatory and evidence framework.
Retrieve package insert: Download the source label or package insert to establish the approved (or intended) indication, which is currently absent from the record.
Re-run TxGNN on the identified primary active component to obtain a valid repurposing score and indication ranking.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.